Special issue of Future Medicinal Chemistry explores immunotherapy edit articleEurekAlert (press release)The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, oft… Continue reading
DNAinfo |
Former Hollywood Stuntman Raising $10000 For His Stem Cell Therapy
DNAinfo More than 5,000 liver transplants in the United States take place each year, according to the “Stem Cell Therapy for Liver Diseases,” a review article published in the Journal of Stem Cell Research and Therapy. About 20,000 people are waiting for a … Stem Cell Therapy Educational SeminarsCheckbiotech.org (press release) Plant Stem Cell Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024Medgadget (blog) Young Patient With Autism Improves After Stem Cell Therapy ProgramMENAFN.COM WhaTech all 8 news articles » |
|
Cellectis Starts BPDCN Phase I Trial with Gene Edited CAR–T Cell Therapy
Genetic Engineering & Biotechnology News (blog) Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR–T cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from … |
|
Immunotherapy, Nanotech Combine to Kill Cancer Cells More Effectively
Genetic Engineering & Biotechnology News The specific photothermal immunotherapy was developed by Duke researchers and uses lasers and gold nanostars to heat and kill tumors in combination with an immunotherapeutic drug. The technique works based on the ability of nanoparticles to … |
Forbes |
5 Important Healthcare Predictions For 2018
Forbes Ng says, “CAR-T allows personalized cancer therapy by programming body’s T cells to attack tumor cells based on unique antigens expressed on one’s own tumor cells”. Blockchain technology entering the healthcare arena is another space to watch, for its … |
Endpoints News |
With CAR–T marketing looming, early study highlights potential of TCR engineering
Endpoints News This week, a research team led by the NIH’s Steven Rosenberg — whose work has been used as a basis of Kite Pharma’s pioneering CAR-T — rolled out early proof-of-concept data from a small human study using a CD4+ T cell adapted with a T cell receptor … |